In February 2025, management approved a restructuring plan in furtherance of our ongoing program to improve operating performance (the "February 2025 Plan"). The February 2025 Plan primarily impacted our operations in the U.S. and included the elimination of certain positions, the consolidation of certain functions, and the relocation of certain operations to lower cost locations. As of September 30, 2026, the February 2025 Plan was substantially complete, with majority of planned actions implemented. The remaining activities relate primarily to administrative matters and the settlement of outstanding employee-related obligations, which are expected to be completed by the end of 2026. From February 2025 through September 30, 2026, cumulative restructuring costs under the February 2025 Plan were $47.2 million, primarily representing employee termination benefits and facility exit costs. We do not expect to incur material additional costs under the February 2025 Plan.


	Life Science		Clinical Diagnostics		Total
Balances as of December 31, 2025	$	2.7	$	10.4	$	13.1
Charged to expense - employee termination benefits	0.5		—		0.5
Adjustments to expense	0.2		0.1		0.3
Cash payments	(2.7)		(7.7)		(10.4)
Foreign currency adjustments	(0.1)		0.1		—
Balances as of September 30, 2026	$	0.6	$	2.9	$	3.5

In July 2026, management approved a new restructuring plan (the "July 2026 Plan"), as part of the Company's ongoing program to improve operating performance and strengthen our competitive position. The July 2026 Plan impacts our operations throughout the world and includes the elimination of certain positions, the consolidation of certain functions, and the closure of various facilities. We expect to incur total pre-tax costs of approximately $80 million to $90 million, which we anticipate will consist primarily of one-time termination benefits, including cash severance payments, healthcare benefits, and related transition assistance. The restructuring plan is expected to be substantially completed by the end of fiscal year 2027.

Restructuring costs incurred under the July 2026 Plan during the three and nine months ended September 30, 2026, which also represent cumulative costs incurred since inception, were as follows (in millions):


	Life Science		Clinical Diagnostics		Total
Balances as of December 31, 2025	$	—	$	—	$	—
Charged to expense - employee termination benefits	26.3		46.4		72.7

Cash payments	(4.1)		(4.5)		(8.6)
Foreign currency adjustments	(0.5)		(0.8)		(1.3)
Balances as of September 30, 2026	$	21.7	$	41.1	$	62.8

As of September 30, 2026, total restructuring liabilities of $69.0 million consisted of $53.5 million recorded in Accrued payroll and employee benefits and $15.5 million in Other long-term liabilities in the condensed consolidated balance sheets. Restructuring-related expense for all plans in aggregate is allocated in the condensed consolidated statements of income (loss) as follows (in millions):


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2026		2025		2026		2025
Cost of goods sold	$	24.7	$	(0.6)	$	24.5	$	4.1
Selling, general and administrative expense	41.4		2.4		42.2		20.3
Research and development expense	11.1		0.7		9.4		13.7
Total restructuring expense	$	77.2	$	2.5	$	76.1	$	38.1